» Articles » PMID: 27773937

Effect of Phentermine on Weight Reduction in a Pediatric Weight Management Clinic

Overview
Specialty Endocrinology
Date 2016 Oct 25
PMID 27773937
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Phentermine is the most widely prescribed obesity medication in adults, yet studies of its use in the pediatric population are limited. We conducted a retrospective chart review of adolescents with obesity treated in a pediatric weight management clinic to examine the weight loss effectiveness of phentermine added to standard of care (SOC) lifestyle modification therapy versus SOC alone. All patients receiving phentermine plus SOC (n=25) were matched with a comparison group receiving only SOC (n=274). Differences at 1, 3 and 6 months were evaluated using generalized estimated equations adjusting for age, sex and baseline body mass index (BMI) and robust variance standard error estimates for confidence intervals and P-values. Phentermine use was associated with a greater percent change in BMI at 1 month (-1.6%; 95% confidence interval (CI): -2.6, -0.6%; P=0.001), 3 months (-2.9%; 95% CI: -4.5, -1.4%; P<0.001) and 6 months (-4.1%; 95% CI: -7.1, -1.0%; P=0.009) compared with SOC alone, with no differences in systolic or diastolic blood pressure between groups. Heart rate was higher at all time-points in the phentermine plus SOC compared with SOC-only group. These data suggest that short-term use of phentermine added to SOC may enhance weight loss in adolescents with obesity in the clinical setting.

Citing Articles

Current Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review.

Niechcial E, Wais P, Bajtek J, Kedzia A Nutrients. 2024; 16(23).

PMID: 39683477 PMC: 11644648. DOI: 10.3390/nu16234084.


Pediatric Obesity Treatment: Considerations for Diabetes Educators and Clinicians.

Laroche H, Fernandez C, Sweeney B, Dreyer Gillette M, Hampl S Diabetes Spectr. 2024; 37(4):313-324.

PMID: 39649695 PMC: 11623046. DOI: 10.2337/dsi24-0005.


Special considerations for the child with obesity: An Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024.

Cuda S, Censani M, OHara V, Paisley J, Kharofa R, Conroy R Obes Pillars. 2024; 11:100113.

PMID: 38953014 PMC: 11216014. DOI: 10.1016/j.obpill.2024.100113.


Effective and appropriate use of weight loss medication in pediatric obesity: a narrative review.

Chung Y J Yeungnam Med Sci. 2024; 41(3):158-165.

PMID: 38952016 PMC: 11294794. DOI: 10.12701/jyms.2024.00353.


Effectiveness and predictors of weight loss response to phentermine plus lifestyle modifications among youth in a paediatric weight management clinical setting.

Bomberg E, Clark J, Rudser K, Gross A, Kelly A, Fox C Pediatr Obes. 2024; 19(8):e13143.

PMID: 38886982 PMC: 11239309. DOI: 10.1111/ijpo.13143.


References
1.
Sherafat-Kazemzadeh R, Yanovski S, Yanovski J . Pharmacotherapy for childhood obesity: present and future prospects. Int J Obes (Lond). 2012; 37(1):1-15. PMC: 3522799. DOI: 10.1038/ijo.2012.144. View

2.
Chanoine J, Hampl S, Jensen C, Boldrin M, Hauptman J . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005; 293(23):2873-83. DOI: 10.1001/jama.293.23.2873. View

3.
Hendricks E, Greenway F, Westman E, Gupta A . Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011; 19(12):2351-60. DOI: 10.1038/oby.2011.94. View

4.
Antelmi I, Paula R, Shinzato A, Peres C, Mansur A, Grupi C . Influence of age, gender, body mass index, and functional capacity on heart rate variability in a cohort of subjects without heart disease. Am J Cardiol. 2004; 93(3):381-5. DOI: 10.1016/j.amjcard.2003.09.065. View

5.
Rauh J, Lipp R . Chlorphentermine as an anorexigenic agent in adolescent obesity. Report of its efficacy in a double-blind study of 30 teen-agers. Clin Pediatr (Phila). 1968; 7(3):138-40. DOI: 10.1177/000992286800700305. View